Copenhagen, Denmark–based CathVision plans to use the funds to advance commercial operations for driving the adoption of its ECGenius system for EP recording. Additionally, funds will go toward developing artificial intelligence (AI)-powered analytic modules to provide electrophysiologists with automated analysis during cardiac ablation procedures.
“Our investors have witnessed the evolution of our company and technology in recent years,” Mads Matthiesen, CathVision CEO, said in a news release. “Reinvesting in the company demonstrates confidence in our innovation, ongoing development, and ability to advance adoption of the ECGenius System throughout the United States as we focus on empowering physicians to diagnose, characterize, and treat cardiac arrhythmias more effectively. We are expanding our sales team, building our U.S. presence, and furthering the development of analytic modules.”
What is the ECGenius system?
CathVision’s ECGenius system features a proprietary hardware amplifier capable of acquiring high-fidelity, low-noise cardiac electrograms. The company said its technology offers a progression in the quality of cardiac signal acquisition. It’s also supposed to boost the accuracy of electrogram interpretation. The idea is to advance therapy support to help electrophysiologists improve the overall diagnosis and treatment of complex atrial arrhythmias, including AFib.
ECGenius picked up FDA 510(k) clearance in May. CathVision is currently offering the platform in a limited market release and has not confirmed when it will commence a wider release.
“Cardiac ablation is one of the fastest growing markets in healthcare; treatment efficiency and efficacy must improve for physicians to deliver the best possible care for patients with atrial fibrillation and other cardiac arrhythmias,” said Matthieu Bocquet, a founding partner at Lumine Capital. “CathVision’s modern and precise EP recording technology brings more clarity to physicians by delivering clear signals that can be accurately interpreted. This is a necessary step to improve treatment outcomes.”
